Biotech Values

[dewophile]

MYGN

anyone think the oppenheimer downgrade and 8% decline today is a buying opportunity?

the rationale for the downgrade is people won't keep their gyn appointments and demand for cancer screening products will decline as a result (i forget what % of BRCA and lynch syn analyses are driven by gyns but it is significant - maybe 30-40%)

1. i'm not convinced the above thesis is necessarily correct
2. this is a company that stands to gain a great deal imo if/when health reform passes with a bolus of new pts who will now have coverage for such screening
3. I've heard their pitch first hand and it is compelling - particularly for colon/endometrial screening which unlike BRCA (which everyone knows about) stands to grow substantially imo due to increased awareness